Improved formulations of anti-cancer agents 5-Fluorouracil and Oxaliplatin using excipient technology

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/514644

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Chemotherapy plays a key role in cancer treatment, however, problems persist with severe adverse toxic effects. Combinations of anti-cancer agents give better results, but these agents still have major negative effects, for example, on veins and peripheral nerves and they must be given separately. We have developed a novel, all-in-one formulation of Oxaliplatin with 5-Fluorouracil and Leucovorin, with the potential for fewer toxic effects and improved patient care.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2009

Funding Scheme: NHMRC Development Grants

Funding Amount: $202,973.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology And Carcinogenesis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

5-fluorouracil | cancer chemotherapeutic agents | cancer chemotherapy | carcinomas | colon cancer | drug development | endothelial damage | oxaliplatin | pre-clinical

Related Links